SCHEMBL11936746

SCHEMBL11936746

CCc1cc(NC(C)=O)cc(C(=O)O)c1

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CREBBP Q92793 1/20 0.52
MEN1 O00255 3/20 0.50
KMT2A Q03164 3/20 0.50
RXRA P19793 1/20 0.45
RXRB P28702 1/20 0.45
RAB9A P51151 3/20 0.44
LMNA P02545 1/20 0.44
ALDH1A1 P00352 1/20 0.44
GAA P10253 1/20 0.43
PKM P14618 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
NAPRT Q6XQN6 1/20 0.41
HSD17B10 Q99714 1/20 0.41
KDM4E B2RXH2 1/20 0.40
TSHR P16473 1/20 0.40
PTGER1 P34995 1/20 0.40
POLB P06746 2/20 0.40
NR4A1 P22736 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14075740 0.85 LMNA (0.54) MEN1KMT2ARAB9ALMNAALDH1A1
SCHEMBL2735596 0.83 MEN1 (0.56) MEN1KMT2ALMNAALDH1A1GAA
SCHEMBL618917 0.83 L3MBTL1 (0.57) MEN1KMT2ARAB9ALMNAALDH1A1
SCHEMBL1353367 0.79 ALDH1A1 (0.60) MEN1KMT2ARXRARXRBRAB9A
SCHEMBL334347 0.79 RXRA (0.64) MEN1KMT2ARXRARXRBRAB9A
SCHEMBL8036269 0.79 KDM4E (0.56) MEN1KMT2ARAB9ALMNAALDH1A1
SCHEMBL16397403 0.79 MEN1 (0.53) CREBBPMEN1KMT2ARAB9ALMNA
SCHEMBL28177053 0.77 PTGER1 (0.48) MEN1KMT2ARAB9AGAAL3MBTL1
SCHEMBL24505559 0.77 ALDH1A1 (0.51) MEN1KMT2ARAB9ALMNAALDH1A1
SCHEMBL9452430 0.77 LMNA (0.46) MEN1KMT2ARAB9ALMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120231998-A1 ORGANIC COMPOUNDS AND THEIR USES NOVARTIS AG (CH) 2012-09-13 US disclosed
US-8211932-B2 Organic compounds and their uses NOVARTIS AG (CH) 2012-07-03 US disclosed
US-20100331243-A1 ORGANIC COMPOUNDS AND THEIR USES NOVARTIS AG (CH) 2010-12-30 US disclosed
US-20100204159-A1 ORGANIC COMPOUNDS AND THEIR USES NOVARTIS AG (CH) 2010-08-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100331243-A1 ORGANIC COMPOUNDS AND THEIR USES OAT, OTC, AOX1 CREBBP 2421/4885MEN1 2302/4885KMT2A 3407/4885
US-20100204159-A1 ORGANIC COMPOUNDS AND THEIR USES OAT, OTC, AOX1 CREBBP 2421/4885MEN1 2302/4885KMT2A 3407/4885
US-20120231998-A1 ORGANIC COMPOUNDS AND THEIR USES OAT, OTC, AOX1 CREBBP 2421/4885MEN1 2302/4885KMT2A 3407/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.